Conference Reports for NATAP

Back

ID Week Oct 21 - October 25     Gilead Sciences' Commitment to the COVID-19 Pandemic - (11/03/20)   Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients - (11/03/20)   Safety of Remdesivir vs Standard of Care in Patients With Moderate COVID-19 - (11/03/20)   Baseline Characteristics Associated With Clinical Improvement in Hospitalized Patients With Moderate COVID-19 - (11/03/20)   Remdesivir vs Standard Care in Patients With Moderate COVID-19 - (11/03/20)   Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated With Remdesivir - (11/03/20)   Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/20)   COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/20)   HCV Treatment Less Likely for Women, Current Drug Users, Detectable HIV Load - Mark Mascolini (11/02/20)   Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/20)   HAVES VS HAVE-NOTS IN HEALTHCARE COMMUNICATION: EXAMINING THE PARADOX WHERE PLHIV WHO NEED QUALITY DISCUSSIONS WITH THEIR PROVIDERS THE MOST, ACCESS IT THE LEAST - (11/02/20)   Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness - (11/02/20)   Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance - (11/02/20)   Bone mineral density screening in veterans living with HIV : Only One Quarter of US HIV+ Veterans Group Screened for Low BMD - Mark Mascolini (11/02/20)   IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (11/02/20)   SAFETY, EFFICACY, AND DURABILITY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE AS MAINTENANCE THERAPY FOR HIV-1 INFECTION: LATTE-2 WEEK 256 RESULTS - (11/02/20)   HIV-1 RNA BLIPS AND LOW-LEVEL REPLICATION DURING PHASE III/IIIB CABOTEGRAVIR + RILPIVIRINE LONG-ACTING STUDIES ARE SIMILAR TO ORAL 3-DRUG THERAPY AND NOT ASSOCIATED WITH WEEK 48 VIROLOGIC OUTCOME - (11/02/20)   LONG-TERM PATIENT ADHERENCE AND MANAGEMENT OF TREATMENT INTERRUPTIONS WITH LONG-ACTING INJECTABLE CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY IN PHASE 2B/3 STUDIES - (11/02/20)   Association of Aging, Frailty and Place of Residence with Skin, Oral and Gut Microbiome Characteristics and Pathogenicity Reservoirs - (11/02/20)   TREATMENT-RELATED PHYSICAL, EMOTIONAL, AND PSYCHOSOCIAL CHALLENGES AND THEIR IMPACT ON INDICATORS OF QUALITY OF LIFE - (10/30/20)   NO DOSE ADJUSTMENT OF METFORMIN WITH FOSTEMSAVIR COADMINISTRATION BASED ON MECHANISTIC STATIC AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS - (10/30/20)   HEALTH CARE RESOURCE UTILIZATION AND COST OF PEOPLE LIVING WITH HIV (PLWH) IN US COMMERCIAL AND MEDICARE ADVANTAGE HEALTH PLANS - (10/30/20)   Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) - (10/30/20)   Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start - The RoCHaCHa Study, a Pilot Study - (10/30/20)   Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis - (10/30/20)   PATIENT-REPORTED OUTCOMES ON LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: FLAIR 96-WEEK RESULTS - (10/30/20)   Older Age, Comorbidities Predict Hospital Trip for COVID-19 in HIV Group - Mark Mascolini - (10/30/20)   Four in 5 on ART Resume Therapy in Hospital, One Third Change ARVs - Impact of hospitalization on antiretroviral therapy for people living with HIV - Mark Mascolini - (10/30/20)   B/F/TAF Controls HIV in 10 of 10 on Hemodialysis for Kidney Disease - (10/28/20)   SUMMARY OF COVID-RELATED IMPACT ON CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING GLOBAL PHASE IIB and III CLINICAL TRIALS - (10/28/20)   Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF) - (10/28/20)   Increased Diagnosis Acute HIV Through Routine ED Screening & Rapid Linkage to Care & Initiation of HAARTDuring the COVID-19 Pandemic - (10/28/20)   ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/20)   ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability - (10/28/20)   Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)   ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/20)   ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices - (10/28/20)   Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)   PATIENT PERSPECTIVES ON IMPLEMENTATION OF A LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY REGIMEN IN HIV US HEALTHCARE SETTINGS: INTERIM RESULTS FROM THE CUSTOMIZE STUDY - (10/28/20)   Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/28/20)   Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine - (10/28/20)   Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis - (10/26/20)   Who does not show up for followup in an HIV PrEP clinic? More Education Favors Steady PrEP-Bisexuals, Heterosexuals Need More Support - Mark Mascolini (10/26/20)   Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV - (10/26/20)   Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/26/20)   Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1 - (10/26/20)   IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (10/26/20)   Preexisting resistance and week 48 virologic outcomes after switching to B/F/TAF in African American adults with HIV - Frequent Resistance Before B/F/TAF Does Not Dim Week-48 Viral Response - Mark Mascolini (10/26/20)   Empiric Antibiotics Frequent-But Usually Not Needed-for COVID-19 - Mark Mascolini (10/26/20)   Pain in Two Thirds of Older US HIV Group Tied to Comorbidities - Mark Mascolini (10/26/20)   Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with Severe COVID-19 Pneumonia Early Steroids Cut Need for Ventilation, Shorten ICU Stay, With COVID - Mark Mascolini (10/26/20)   Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis- Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - (10/26/20)   One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/26/20)   One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/23/20)   Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/23/20)   Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study - (10/23/20)   Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial - (10/23/20)   QUALITATIVE FINDINGS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY TO EXPLORE PERSPECTIVES OF HEALTHCARE STAFF ON EARLY IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (10/22/20)   Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV Weight Climbs With Switch to Bictegravir Across Baseline Regimens - Mark Mascolini - (10/22/20)   Congestive heart failure in persons living with HIV: are we providing standard of care? Most People With HIV and CHF Get Correct CHF Care-With Notable Exceptions - Mark Mascolini - (10/22/20)   Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/22/20)   HIV Control With Ibalizumab for 7.8 to 9.5 Years With Few Regimen Tweaks - Mark Mascolini - (10/22/20)   Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - Mark Mascolini - (10/22/20)   Risk Factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain - Mark Mascolini -(10/22/20)